CD38-targeted antibody-drug conjugate 
Welcome,         Profile    Billing    Logout  
  Companies   Products    Products    Diseases    Trials    News 


«12...3456789101112131415»
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    [VIRTUAL] Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML (Poster Hall (Virtual Meeting)) -  Nov 5, 2020 - Abstract #ASH2020ASH_2410;    
    To overcome these barriers, we developed a robust genetic editing and manufacturing platform for the uniform engineering and expansion of high-quality NK cells derived from induced pluripotent stem cells (iPSCs)...Previously, we reported on our ability to effectively target multiple myeloma with our FT538 program (the iNK defined below), now FDA approved for clinical trials...Collectively, our results show that utilizing the iNK cell platform to uniformly express hnCD16 and IL15RF combined with complete CD38 KO is an effective strategy to promote effective ADCC against CD38+ cells in the absence of fratricide, and that CD38 KO reprograms NK cells for higher oxidative metabolic fitness for improved persistence and anti-tumor function. Furthermore, we have generated proof-of-concept data supporting triple gene-modified iNK cells combined with dara as a novel AML immunotherapy.
  • ||||||||||  Review, Journal:  Immunotherapeutic and Targeted Approaches in Multiple Myeloma. (Pubmed Central) -  Nov 1, 2020   
    Immunotherapeutic approaches have shown substantial promise in recent studies of chimeric antigen receptor T-cell (CAR T-cell) therapy, bispecific antibodies, and antibody drug conjugates targeting B-cell maturation antigen (BCMA). This review will highlight these novel and targeted therapies in MM, with particular focus on PIs, IMIDs, MoAb and BCMA-directed immunotherapy.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Journal, IO Biomarker:  Targeting of CD38 by the tumor suppressor miR-26a serves as a novel potential therapeutic agent in multiple myeloma. (Pubmed Central) -  Oct 28, 2020   
    Daratumumab is the first CD38 antibody drug for monotherapy and combination therapy for patients with multiple myeloma, but eventually resistance develops...In daratumumab-resistant MM cells, CD38 expression was completely restored but failed to correlate with daratumumab-induced cell death. Therefore, a therapeutic strategy to confer selection pressure to maintain low CD38 expression in MM cells may have clinical benefit.
  • ||||||||||  Revlimid (lenalidomide) / BMS
    Review, Journal:  Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020. (Pubmed Central) -  Oct 21, 2020   
    Lenalidomide monotherapy is the only drug approved in that setting, but many innovations are expected...Among the questions that will need to be answered in the years to come is the position of these new treatments in the therapeutic strategy, as well as the role of minimal residual disease-driven strategies which will be a key issue to elucidate. Through this review, we chose to enumerate and comment on the most recent advances in MM therapeutics which have undergone major transformations over the past decade.
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK, Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
    [VIRTUAL] How I treat relapsed and/or refractory multiple myeloma () -  Oct 17, 2020 - Abstract #SOHOItaly2020SOHO_Italy_3;    
    Hematologic responses were high in these heavily pretreated pts, while more than one-fifth of them also achieved a renal response. Abstract The expanding therapeutic landscape of relapsed and/or refractory multiple myeloma (RRMM) has contributed to significant improvements in patient outcomes These have included combinations of proteasome inhibitors (PIs), immunomodulatory drugs (IMiDs), monoclonal antibodies (mAbs), histone deacetylase inhibitors, and/or alkylating agents More recently, the approval of the first-in-class nuclear export inhibitor selinexor and the first-in-class B-cell maturation antigen (BCMA) antibody-drug conjugate (ADC) belantamab mafodotin has helped address the current unmet need in patients refractory to PI, IMiD, and anti-CD38 mAb directed therapy, otherwise known as triple class refractory myeloma With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK, Xpovio (selinexor) / Ono Pharma, Karyopharm, Antengene
    Journal:  How I treat relapsed and/or refractory multiple myeloma. (Pubmed Central) -  Oct 15, 2020   
    With the growing number of treatment options in the RRMM therapeutic landscape, the choice and sequencing of drugs and combinations has become increasingly complex. In this review we discuss our approach and considerations in the treatment of both early and late RRRM based on best available data and our clinical experience.
  • ||||||||||  Blenrep (belantamab mafodotin) / GSK
    [VIRTUAL] Immunotherapy in Multiple Myeloma - Live Q&A (Channel 10 (Virtual Meeting)) -  Oct 11, 2020 - Abstract #ASH2020ASH_33;    
    Some of these cell surface antigens are also internalized, making them ideal candidates for antibody'“drug conjugates (ADC) such as belantamab mafodotin, conjugated with auristatin F and targeting BCMA...Bispecifics targeting the MM antigens BCMA and GPRC5d have already demonstrated deep and durable responses in heavily pretreated patients. Bispecifics targeting CD38 and FCHR5 as well as trispecifics are under investigation.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Journal:  Targeting CD38 with Daratumumab in Refractory Systemic Lupus Erythematosus. (Pubmed Central) -  Oct 9, 2020   
    Significant depletion of long-lived plasma cells, reduction of interferon type I activity, and down-regulation of T-cell transcripts associated with chronic inflammation were documented. (Supported by the Deutsche Forschungsgemeinschaft and others.).
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Review, Journal:  Monoclonal and Bispecific Anti-BCMA Antibodies in Multiple Myeloma. (Pubmed Central) -  Sep 25, 2020   
    Experimental approaches targeting BCMA are currently being investigated and include antibody-drug conjugates (ADCs), bispecific antibodies (bsAbs) and genetically engineered T-cells with chimeric antigen receptors (CAR). In this review we summarize the more recent findings about BCMA biologic rationale as a therapeutic target and report the updated results of preclinical and clinical studies focused on ADCs and bsAbs targeting BCMA.
  • ||||||||||  cyclophosphamide intravenous / Generic mfg.
    Review, Journal:  Novel Approaches to Improve Myeloma Cell Killing by Monoclonal Antibodies. (Pubmed Central) -  Sep 10, 2020   
    The use of trans-retinoic acid, the cyclophosphamide or the combination of anti-CD47 and anti-CD137 mAbs have given the rationale to design these types of combinations therapies in MM patients in the future. In conclusion, a better understanding of the mechanism of action of the mAbs will allow us to develop novel therapeutic approaches to improve their response rate and to overcome their resistance in MM patients.
  • ||||||||||  STI-6129 / Sorrento
    Trial completion date:  Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis (clinicaltrials.gov) -  Sep 8, 2020   
    P1,  N=60, Not yet recruiting, 
    In conclusion, a better understanding of the mechanism of action of the mAbs will allow us to develop novel therapeutic approaches to improve their response rate and to overcome their resistance in MM patients. Trial completion date: Aug 2026 --> Dec 2021
  • ||||||||||  Journal, CAR T-Cell Therapy:  CAR-T cell therapy for multiple myeloma: a consensus statement from The European Myeloma Network. (Pubmed Central) -  Aug 5, 2020   
    Currently, CAR-T cell therapy for multiple myeloma remains experimental, but once this strategy is approved in relapsed/refractory multiple myeloma, this will become one of the most important indications for this therapy in Europe and world-wide. This manuscript proposes practical considerations for the use of CAR-T cell therapy in multiple myeloma, and discusses several important issues for the future development of this strategy.
  • ||||||||||  MEN1112 / Menarini, Oxford BioTherapeutics
    Review, Journal, IO Biomarker:  CD157: From Myeloid Cell Differentiation Marker to Therapeutic Target in Acute Myeloid Leukemia. (Pubmed Central) -  Aug 4, 2020   
    The aim of this review is to provide an overview of the immunoregulatory functions of human CD157/BST-1 in physiological and pathological conditions. We then focus on CD157 expression in hematological tumors highlighting its emerging role in the interaction between acute myeloid leukemia and extracellular matrix proteins and its potential utility for monoclonal antibody targeted therapy in this disease.
  • ||||||||||  Darzalex IV (daratumumab) / J&J
    Clinical, Journal:  CD38-targeted therapy with daratumumab reduces autoantibody levels in multiple myeloma patients. (Pubmed Central) -  Aug 4, 2020   
    We found that 6 out of 41 (15%) had detectable autoantibodies before initiation of daratumumab therapy, and that these autoantibodies rapidly disappeared in 5 out of 6 patients during daratumumab treatment. Our data provide support for the evaluation of daratumumab in patients with autoantibody-dependent autoimmune disorders.